Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RIC BMT with PTCy for PID and IBMFS
NCT04232085Phase 2Recruiting
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center
- Start
- Feb 2020
- Primary completion
- Dec 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of cyclophosphamide in primary immunodeficiency disorder (PID), immune dysregulation polyendocrinopathy enteropathy X-linked syndrome (IPEX), inherited bone marrow failure syndrome (IBMFS), Fanconi anemia (FA), short telomere syndrome (STS), sponsored by Sidney Kimmel Comprehensive Cancer Center. Started Feb 2020; status: recruiting.
02
Drugs
cyclophosphamide
03
Conditions
primary immunodeficiency disorder (PID)immune dysregulation polyendocrinopathy enteropathy X-linked syndrome (IPEX)inherited bone marrow failure syndrome (IBMFS)Fanconi anemia (FA)short telomere syndrome (STS)
Beyond the preview
Go deeper on NCT04232085.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04232085.